Method of treating type 1 diabetes by administering NKp46 polypeptide

Ofer Mandelboim; Angel Porgador; Yaakov Naparstek; Chamutal Gur

Method of treating type 1 diabetes by administering NKp46 polypeptide

Ofer Mandelboim (Inventor)
, Angel Porgador (Inventor)
, Yaakov Naparstek (Inventor)
, Chamutal Gur (Inventor)

The Shraga Segal Department of Microbiology and Immunology

Ben-Gurion University of the Negev

Research output: Patent

Abstract

The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.

Original language	English
Patent number	US8980244B2
State	Published - 1 Mar 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@misc{edc9c0049697453088881549b8c8ebaf,

title = "Method of treating type 1 diabetes by administering NKp46 polypeptide",

abstract = "The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.",

author = "Ofer Mandelboim and Angel Porgador and Yaakov Naparstek and Chamutal Gur",

note = "US Patent 8,980,244; US8980244B2",

year = "2015",

month = mar,

day = "1",

language = "English",

type = "Patent",

}

TY - PAT

T1 - Method of treating type 1 diabetes by administering NKp46 polypeptide

AU - Mandelboim, Ofer

AU - Porgador, Angel

AU - Naparstek, Yaakov

AU - Gur, Chamutal

N1 - US Patent 8,980,244

PY - 2015/3/1

Y1 - 2015/3/1

N2 - The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.

AB - The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.

M3 - Patent

M1 - US8980244B2

ER -

Method of treating type 1 diabetes by administering NKp46 polypeptide

Abstract

UN SDGs

Fingerprint

Cite this